SG11201704094QA - Myostatin or activin antagonists for the treatment of sarcopenia - Google Patents

Myostatin or activin antagonists for the treatment of sarcopenia

Info

Publication number
SG11201704094QA
SG11201704094QA SG11201704094QA SG11201704094QA SG11201704094QA SG 11201704094Q A SG11201704094Q A SG 11201704094QA SG 11201704094Q A SG11201704094Q A SG 11201704094QA SG 11201704094Q A SG11201704094Q A SG 11201704094QA SG 11201704094Q A SG11201704094Q A SG 11201704094QA
Authority
SG
Singapore
Prior art keywords
sarcopenia
myostatin
treatment
activin antagonists
activin
Prior art date
Application number
SG11201704094QA
Inventor
Patrick Kortebein
Daniel Rooks
Lloyd B Klickstein
Ronenn Roubenoff
David Glass
Estelle Trifilieff
Dimitris Papanicolaou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024187&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201704094Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201704094QA publication Critical patent/SG11201704094QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201704094QA 2014-12-08 2015-12-04 Myostatin or activin antagonists for the treatment of sarcopenia SG11201704094QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462088802P 2014-12-08 2014-12-08
PCT/IB2015/059369 WO2016092439A1 (en) 2014-12-08 2015-12-04 Myostatin or activin antagonists for the treatment of sarcopenia

Publications (1)

Publication Number Publication Date
SG11201704094QA true SG11201704094QA (en) 2017-06-29

Family

ID=55024187

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704094QA SG11201704094QA (en) 2014-12-08 2015-12-04 Myostatin or activin antagonists for the treatment of sarcopenia

Country Status (17)

Country Link
US (1) US20170260275A1 (en)
EP (1) EP3229907A1 (en)
JP (1) JP2017538701A (en)
KR (1) KR20170094292A (en)
CN (1) CN106999589A (en)
AU (2) AU2015358939A1 (en)
BR (1) BR112017011411A2 (en)
CA (1) CA2969800A1 (en)
CL (1) CL2017001438A1 (en)
IL (1) IL252507A0 (en)
MX (1) MX2017007519A (en)
PH (1) PH12017500965A1 (en)
RU (1) RU2017123880A (en)
SG (1) SG11201704094QA (en)
TN (1) TN2017000217A1 (en)
TW (1) TW201627007A (en)
WO (1) WO2016092439A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP3056513A1 (en) 2008-04-11 2016-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
RU2658504C9 (en) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules
TW202237660A (en) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE Fc RII-SPECIFIC Fc ANTIBODY
WO2014163101A1 (en) 2013-04-02 2014-10-09 中外製薬株式会社 Fc region variant
KR20180054923A (en) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109153713B (en) 2016-03-10 2022-12-27 艾科赛扬制药股份有限公司 Activin type 2 receptor binding proteins and uses thereof
TW202300168A (en) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Composition for prophylaxis or treatment of il-8 related diseases
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
JOP20190152A1 (en) * 2016-12-21 2019-06-20 Novartis Ag Myostatin, activin or activin receptor antagonists for use in treating obesity and related conditions
KR101917794B1 (en) 2018-05-10 2018-11-13 한국과학기술원 Pharmaceutical composition for improving, preventing or treating muscle related disease comprising ginsenoside Rh2
KR101966117B1 (en) 2018-05-25 2019-04-05 (주)녹십자웰빙 Composition comprising extract of processed ginseng for stimulating of myogenesis
KR102017282B1 (en) 2019-01-28 2019-09-02 (주)녹십자웰빙 Composition comprising extract of processed ginseng for stimulating of myogenesis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518422A (en) * 2005-12-06 2009-05-07 アムジェン インコーポレイテッド Use of myostatin antagonist
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
TW201907946A (en) * 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 Variants derived from ActRIIB and their uses
TWI454479B (en) * 2007-03-06 2014-10-01 Amgen Inc Variant activin receptor polypeptides and uses thereof
AU2010243697B2 (en) 2009-04-27 2013-05-23 Novartis Ag Compositions and methods for increasing muscle growth
AR081556A1 (en) * 2010-06-03 2012-10-03 Glaxo Group Ltd HUMANIZED ANTIGEN UNION PROTEINS
PL2726099T3 (en) * 2011-07-01 2018-12-31 Novartis Ag Method for treating metabolic disorders
PE20150642A1 (en) * 2012-06-11 2015-05-26 Amgen Inc ANTIGEN-BINDING PROTEINS, ANTAGONISTS OF THE DUAL ACTION RECEPTOR AND THEIR USES
EP3033358A2 (en) * 2013-08-14 2016-06-22 Novartis AG Methods of treating sporadic inclusion body myositis
TW201622746A (en) * 2014-04-24 2016-07-01 諾華公司 Methods of improving or accelerating physical recovery after surgery for hip fracture

Also Published As

Publication number Publication date
WO2016092439A1 (en) 2016-06-16
AU2019200082A1 (en) 2019-01-31
RU2017123880A (en) 2019-01-10
TN2017000217A1 (en) 2018-10-19
AU2015358939A1 (en) 2017-06-15
PH12017500965A1 (en) 2017-10-18
CA2969800A1 (en) 2016-06-16
IL252507A0 (en) 2017-07-31
CN106999589A (en) 2017-08-01
JP2017538701A (en) 2017-12-28
TW201627007A (en) 2016-08-01
KR20170094292A (en) 2017-08-17
CL2017001438A1 (en) 2018-02-16
RU2017123880A3 (en) 2019-08-29
US20170260275A1 (en) 2017-09-14
EP3229907A1 (en) 2017-10-18
MX2017007519A (en) 2017-08-22
BR112017011411A2 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
IL252507A0 (en) Myostatin or activin antagonists for the treatment of sarcopenia
HK1232147A1 (en) Cenicriviroc for the treatment of fibrosis
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
LT3227675T (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
HK1244485A1 (en) Combinations for the treatment of neuroblastoma
GB201608885D0 (en) Treatment
GB201402179D0 (en) Surface treatment
SG11201702700UA (en) Methods for the treatment of peri-implantitis
SI3200783T1 (en) Erythromelalgia treatment
PL3151899T3 (en) Device for the treatment of esophageal stenoses
IL233380A (en) Glove for cleaning surfaces
IL252487A0 (en) Arylalkylamine compounds for use in the prevention or treatment of cancer
ZA201608407B (en) Stain treatment compositions
GB201411027D0 (en) Treatment
GB201412010D0 (en) Treatment of hypertransaminasemia
ZA201608405B (en) Stain treatment compositions
HK1217430A1 (en) Surface treatment agent
PL3194551T3 (en) Solid composition for textile treatment
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
GB201412270D0 (en) Finishing treatment
GB201413317D0 (en) Atheroscierosis treatment